Equities

Ocular Therapeutix Inc

Ocular Therapeutix Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.60
  • Today's Change-0.36 / -3.28%
  • Shares traded627.61k
  • 1 Year change+403.56%
  • Beta1.2204
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

  • Revenue in USD (TTM)61.10m
  • Net income in USD-138.36m
  • Incorporated2006
  • Employees267.00
  • Location
    Ocular Therapeutix Inc15 Crosby DriveBEDFORD 01730United StatesUSA
  • Phone+1 (781) 357-4000
  • Fax+1 (781) 357-4001
  • Websitehttps://www.ocutx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Phibro Animal Health Corp1.05bn17.41m1.03bn1.94k59.524.0019.270.98860.42930.429325.826.381.082.606.75539,568.101.803.932.204.9031.4731.181.663.771.692.200.647256.454.074.21-92.59-46.356.650.8548
Collegium Pharmaceutical Inc576.65m99.89m1.04bn197.0016.094.434.381.732.302.3012.436.700.50878.143.283,041,853.008.812.7914.584.8061.9450.8817.325.161.043.690.71850.0022.1715.11292.60---54.77--
Innoviva Inc352.75m64.59m1.26bn112.0029.251.8812.063.570.68790.68794.7810.680.29161.144.443,149,509.005.3426.245.9828.5387.93--18.3176.841.641.930.4011---6.303.53-15.99-14.57----
Tilray Brands Inc812.04m-212.62m1.26bn2.65k--0.3524--1.56-0.2746-0.27461.033.970.18752.318.73306,429.10-4.64---5.15--29.42---24.78--1.57-1.160.0953--25.80--83.14------
ANI Pharmaceuticals Inc538.95m22.95m1.30bn642.0051.922.8515.242.411.191.1927.9322.810.60551.813.18839,490.603.04-2.833.56-3.3561.3460.185.01-6.153.073.100.3725--53.8719.28131.250.17549.08--
Avadel Pharmaceuticals PLC (ADR)95.15m-106.22m1.57bn154.00--22.31--16.49-1.17-1.171.040.73060.53080.69415.41617,850.60-59.26-40.21-80.97-47.9994.62---111.64-374.752.52-10.250.00-----22.99-16.59------
Ocular Therapeutix Inc61.10m-138.36m1.71bn267.00--4.52--27.97-1.09-1.090.52492.430.1912.362.12228,827.70-43.26-46.70-47.93-54.1890.8489.36-226.46-228.6516.55-11.300.1509--13.4996.60-13.65--26.37--
Immunocore Holdings PLC - ADR281.45m-53.44m1.73bn497.00--4.82--6.16-1.07-1.075.557.180.35560.56795.56566,303.60-6.75-27.55-8.35-36.8299.41---18.99-97.125.15--0.5495--43.0551.23-5.22--2.85--
Harrow Inc154.15m-33.58m1.85bn315.00--31.53--11.97-0.9508-0.95084.381.650.5814.954.39489,352.40-12.66-10.86-14.77-12.7171.1670.75-21.78-15.352.43-0.35180.7608--46.9525.77-73.30--143.88--
Tarsus Pharmaceuticals Inc83.37m-150.07m1.87bn244.00--7.40--22.39-4.43-4.432.436.630.2947--5.36341,696.70-53.05-31.56-60.10-33.8292.50---180.00-242.596.99--0.221---32.42---118.86--279.39--
Endo Inc-100.00bn-100.00bn1.93bn3.00k--1.05----------23.99------------------------1.52--0.5697---13.25--15.87------
Supernus Pharmaceuticals Inc651.97m59.71m2.02bn652.0034.272.0114.143.101.071.0711.7118.240.49620.96894.54999,957.104.544.955.836.4189.0488.619.1612.841.98--0.00---8.958.24-97.83-58.81-8.17--
Harmony Biosciences Holdings Inc681.88m122.63m2.05bn246.0017.003.4313.943.002.112.1111.7510.460.799424.269.172,771,866.0014.387.4617.129.0878.6580.5817.9810.463.20--0.23450.0032.93---28.99---25.31--
Ligand Pharmaceuticals Inc133.48m42.14m2.33bn58.0055.502.8830.1917.482.222.227.3342.820.16430.47894.082,301,345.005.1912.325.3512.9991.8281.6531.5780.3215.81--0.00002---33.09-12.181,131.21-17.8642.63--
Amphastar Pharmaceuticals Inc723.55m157.72m2.35bn1.76k16.163.2311.133.253.013.0113.7915.040.46842.835.60410,873.9010.289.4211.8811.5652.9847.8321.9515.232.619.420.45060.0029.1416.9450.51---4.00--
Data as of Nov 12 2024. Currency figures normalised to Ocular Therapeutix Inc's reporting currency: US Dollar USD

Institutional shareholders

49.19%Per cent of shares held by top holders
HolderShares% Held
Summer Road LLCas of 30 Jun 202414.89m9.55%
Deep Track Capital LPas of 30 Jun 202412.72m8.16%
BlackRock Fund Advisorsas of 30 Jun 202410.51m6.74%
The Vanguard Group, Inc.as of 30 Sep 20248.38m5.38%
Avoro Capital Advisor LLCas of 30 Jun 20248.06m5.17%
Opaleye Management, Inc.as of 30 Jun 20245.31m3.40%
Logos Global Management LPas of 30 Jun 20245.15m3.30%
Citadel Advisors LLCas of 30 Jun 20244.05m2.60%
SSgA Funds Management, Inc.as of 30 Jun 20243.92m2.52%
Adage Capital Management LPas of 30 Jun 20243.70m2.37%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.